Alnylam Pharmaceuticals
ALNY
357 hedge funds and large institutions have $15.8B invested in Alnylam Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 126 increasing their positions, 129 reducing their positions, and 49 closing their positions.
4% more call options, than puts
Call options by funds: $136M | Put options by funds: $131M
2% less repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 129
4% less capital invested
Capital invested by funds: $16.5B → $15.8B (-$743M)
3.67% less ownership
Funds ownership: 97.21% → 93.54% (-3.7%)
5% less funds holding
Funds holding: 375 → 357 (-18)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
35% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$120M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$34.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$21.3M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$19.6M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$86.1M |
| 2 |
Goldman Sachs
New York
|
-$70.7M |
| 3 |
SPC
Slate Path Capital
New York
|
-$52.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$52.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$47.5M |
ALNY Hedge Fund Activity: Q3 2020 in Review
357 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2020, worth a combined $15.8B — down 4.5% from $16.5B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of ALNY and 32 opened new positions — a net loss of 17 holders — while 129 trimmed existing stakes and 126 added.
The largest buyer was Massachusetts Financial Services, adding an estimated $120M. The largest seller was Fidelity Investments, cutting an estimated $86.1M.
- 357 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2020, down from 375 in Q2 2020.
- Funds reported $15.8B of Alnylam Pharmaceuticals stock for Q3 2020, down 4.5% quarter-over-quarter.
- 32 funds opened new Alnylam Pharmaceuticals positions in Q3 2020 and 49 closed out, a net change of -17 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2020 was Massachusetts Financial Services, an estimated $120M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2020 was Fidelity Investments, an estimated $86.1M sold.
Based on aggregated 13F filings for Q3 2020.